—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Ultragenyx (RARE) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for RARE, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.84 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How RARE has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.84 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Ultragenyx moved 0.84% on average · correlation 0.10 · higher than 79% of US names
  • Beta, last 3 months 0.53 less rate-sensitive lately than over the year
  • On the 10 worst bond days −1.17% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.74% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · United States · 8 names with week and year-to-date

Peer group

Biotechnology · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against RARE on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Ultragenyx

RARE in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Ultragenyx develops medicines for rare and ultra-rare genetic disorders, selling several approved biologics and advancing a pipeline of gene-therapy candidates through mid-to-late-stage trials. Approved products treat conditions such as a phosphate-wasting bone disease, an enzyme deficiency and a fatty-acid metabolism disorder, while trial candidates target diseases including Sanfilippo syndrome and Angelman syndrome. It licenses some programmes to partners such as Kyowa Kirin and Regeneron and operates from a base in Novato, California.
Where it sits in the stack
Ultragenyx carries no seat in Rubin or Halo, our AI-focused indices, so it sits outside the build-out stack entirely; it belongs to the Healthcare sector, within the Biotechnology industry sleeve of our wider universe.
Who it is priced against
Closelooknet's peer group for Ultragenyx has not been set; the market often compares it with other rare-disease specialists such as BioMarin, which follows a similar model of niche approvals and gene-therapy pipelines.
Why Closelooknet tracks it
Ultragenyx holds a Russell 1000 seat but no Rubin or Halo place, and its Closelooknet score has not yet been built; the diary has not quoted it in any edition, so coverage stays limited to the index listing.
What the diary watches
The diary watches whether the recent share decline and the lowered analyst price target reflect a lasting reassessment of the pipeline, or a short-term reaction to trial or funding news.

Ultragenyx (RARE) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 14 analyst actions on the wire · latest: price target by Evercore ISI, 2026-09-21

The Street on this name

Analyst actions and the latest print for RARE from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Evercore ISI — target 18 from 16 Target raised to $18 from $16 (+22.7% to spot) 2026-09-21
  • Price target Barclays — target 35 from 32 Target raised to $35 from $32 (+141.2% to spot) 2026-09-21
  • Price target Canaccord — target 39 Target set to $39 (+169% to spot) 2026-09-18

14 actions on the analyst wire since 2026-08-13: 14 target changes. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Ultragenyx (RARE)?

Ultragenyx trades as RARE on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is RARE in a Closelooknet index?

Not currently — Ultragenyx is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does RARE trade against its moving averages?

Downtrend stack: Trades -35.6% vs the 50-day and -41.1% vs the 200-day average, 63.6% below the 52-week high and +13.9% off the 52-week low; a death cross printed 8 sessions ago. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Ultragenyx trade when bond yields rise?

Over the past year Ultragenyx had a beta of 0.84 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 79% of US names. On the 10 sessions in which long bonds fell most it moved −1.17% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Ultragenyx do?

Ultragenyx develops medicines for rare and ultra-rare genetic disorders, selling several approved biologics and advancing a pipeline of gene-therapy candidates through mid-to-late-stage trials. Approved products treat conditions such as a phosphate-wasting bone disease, an enzyme deficiency and a fatty-acid metabolism disorder, while trial candidates target diseases including Sanfilippo syndrome and Angelman syndrome. It licenses some programmes to partners such as Kyowa Kirin and Regeneron and operates from a base in Novato, California. Closelooknet's peer group for Ultragenyx has not been set; the market often compares it with other rare-disease specialists such as BioMarin, which follows a similar model of niche approvals and gene-therapy pipelines.

Where does Ultragenyx sit in the AI build-out?

Ultragenyx carries no seat in Rubin or Halo, our AI-focused indices, so it sits outside the build-out stack entirely; it belongs to the Healthcare sector, within the Biotechnology industry sleeve of our wider universe. Ultragenyx holds a Russell 1000 seat but no Rubin or Halo place, and its Closelooknet score has not yet been built; the diary has not quoted it in any edition, so coverage stays limited to the index listing.

What has Wall Street done on Ultragenyx recently?

The most recent analyst action on Ultragenyx on the Closelooknet wire is a price target by Evercore ISI on 2026-09-21 (target 18 from 16). 14 actions on the analyst wire since 2026-08-13: 14 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for RARE, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.